

# Icanemab-irmb (Leqembi)

REFERRAL STATUS:  New Referral  Dose or Frequency Change  Order Renewal

Infusion Office Preference: \_\_\_\_\_

## PATIENT INFORMATION

Date: \_\_\_\_\_ Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_

NKDA Allergies: \_\_\_\_\_ Weight (lbs / kg): \_\_\_\_\_ Height: \_\_\_\_\_

Patient Status:  New to Therapy  Continuing Therapy - Last Treatment Date: \_\_\_\_\_ Next Due Date: \_\_\_\_\_

## DIAGNOSIS AND ICD 10 CODE

Alzheimer's disease with early onset ICD 10 Code: G30.0

Mild Cognitive Impairment, So stated ICD 10 Code: G31.84

other ICD10 Code: \_\_\_\_\_ Description: \_\_\_\_\_

**G30.X CODES BELOW REQUIRE SECONDARY F02.8x DIAGNOSIS CODE- PLEASE SELECT ONE FROM EACH COLUMN**

<b>→</b>	<u>Secondary</u>
<input type="checkbox"/> G30.1 Alzheimer's disease late onset	<input type="checkbox"/> F02.80 Dementia without behavioral disturbance
<input type="checkbox"/> G30.8 Other Alzheimer's disease	<input type="checkbox"/> F02.81 Dementia with behavioral disturbance
<input type="checkbox"/> G30.9 Alzheimer's disease , unspecified	

## REQUIRED DOCUMENTATION

This signed order form by the provider  Patient demographics AND insurance info  Clinical/Progress notes

**Prescriber must indicate that the following requirements have been met (provide supporting documentation)**

Beta Amyloid Pathology Confirmed via:  
↳  Amyloid PET Scan **OR**  CFS Analysis-Date: \_\_\_\_\_ Result: \_\_\_\_\_  
 Cognitive Assessment Used: \_\_\_\_\_ Date: \_\_\_\_\_ Result: \_\_\_\_\_  
 ApoE εε4 Genetic Test - Date: \_\_\_\_\_ Result:  Homozygote  Heterozygote  Noncarrier

MEDICARE REGISTRATION # IF APPLICABLE \_\_\_\_\_

## MEDICATION ORDERS(Note: Only one stage of treatment may be ordered at a time)

<input type="checkbox"/> Stage 1 (Infusions #1-4) ✓ Leqembi 10mg/kg IV every two weeks x 4 doses. Each infusion to be given over one hour. <b>Required Documentation to Initiate this Phase:</b> <input type="checkbox"/> MRI of brain within one year prior to first infusion. Date of MRI: _____ By checking this box, I confirm that Beta Amyloid Pathology has been confirmed via CSF or PET.	<input type="checkbox"/> Stage 2 (Infusions #5 and #6) ✓ Leqembi 10mg/kg IV every two weeks x 2 doses. Each infusion to be given over one hour. <b>Required Documentation to Initiate this Phase:</b> <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #5. I have reviewed the results and clear patient to proceed with infusions #5 and #6.	<input type="checkbox"/> Stage 3 (Infusions #7-13) ✓ Leqembi 10mg/kg IV every two weeks x 7 doses. Each infusion to be given over one hour. <b>Required Documentation to Initiate this Phase:</b> <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #7. I have reviewed the results and clear patient to proceed with infusions #7 through #13.	<input type="checkbox"/> Stage 4 (Infusions #14 & beyond) ✓ Leqembi 10mg/kg IV every two weeks x doses. Each infusion to be given over one hour. <b>Required Documentation to Initiate this Phase:</b> <input type="checkbox"/> By checking this box, I confirm that patient has undergone MRI of brain before dose #14. I have reviewed the results and clear patient to proceed with infusions #14 and beyond as ordered above
---	--	---	---

Fax referral to 866-507-1164 or email to MICreferral@metroinfusioncenter.com

All information contained in this order form is strictly confidential and will become part of the patient's medical record.

Created 8/7/24

**PRE-INFUSION :**

- Confirm baseline MRI results prior to initiation of treatment
- Confirm MRI completed and reviewed by prescriber prior to the 5<sup>th</sup>, 7<sup>th</sup>, and 14<sup>th</sup> treatment
- Measure and record weight prior to each treatment to determine dose
- Hold infusion and notify provider if patient reports:
  - Headache
  - Dizziness
  - Nausea
  - Vision Changes
  - New or worsening confusion

**Post -INFUSION :**

- Educate patient/care partner to report headache, dizziness, nausea, vision changes, or new/worsening confusion.
- Fax infusion record to provider below :

**PRESCRIBER INFORMATION**

Provider Name (print)	Provider Signature**:	Date:
Office Phone	Office Fax	

*\*\*Amyloid Related Imaging Abnormalities (ARIA): Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment with LEQEMBI. Referring physician to monitor patient*

**Fax referral to 866-507-1164 or email to [bionurses@metroinfusioncenter.com](mailto:bionurses@metroinfusioncenter.com)**

All information contained in this order form is strictly confidential and will become part of the patient's medical record.

Created 11/22/23